How often, if ever, do you use DECT to diagnose gout?

Efficacy of IVIG in Dermatomyositis Treatment 1st Placebo controlled RCT 1️⃣79% responder by total improvement score vs. 44% 2️⃣Efficacy sustained thru wk 40 3️⃣6% serious AE - thromboembolic event @RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X

ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ

Dr. Burmester on serendipity in the development of rheumatologic meds. As we study #COVID19, we need to keep our minds open that we don't always find what we want, but we can always learn something to bring us ahead. #ACR20 @Rheumnow. https://t.co/s5WZEjrbnk

Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0

• Changing Patterns of Use of Biologic/Targeted Synthetic DMARDs in Psoriatic Art…

#HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE: - 132 patients, 108 on HCQ - Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways - HCQ may improve vascular health in SLE Abs#0870 #ACR20 @RheumNow https://t.co/ST9n2HGyhM

• Hydroxychloroquine Is Associated with Lower Platelet Activity and Improved Vasc…

CZP tx in axSpA pts showed significant reduction of 82% in the AAU flare rate and MSK symptoms over 96 week C-VIEW trial. #ABS0881 #ACR20 @RheumNow https://t.co/bNFHXbKEuF https://t.co/3Z232vKGPC

• Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis D…

In this study of RA pts w/ b/tsDMARDs tx, continuous decrease in RF titers was assoc'd w/ radiographic remission. Other factors were dse duration<5yrs, pred<5mg/d & time-integrated DAS28ESR. @RheumNow #ACR20 abs0754 https://t.co/u0pgAsK4UX

Important to tailor our approach based on patient preferences, and this abstract shows that geriatric patients have different desires for care! #ACR20 @RheumNow https://t.co/pY3VTeURSS

• https://twitter.com/kdao2011/status/1325071719493668866

Most ignore pharmacists annoying faxes re safety of QT interval with #hydroxycholoroquine likely the right thing to do! @RheumNow #ACR2020 @CRASCRRheum abstr#431. https://t.co/pXBIDOV2MP

SKIPPAIN trial: SEC showed rapid and significant improvement of spinal pain (primary endpt) and ⬇ disease activity in axSpA @RheumNow #ACR20 abs0899 #ACRbest https://t.co/fKSEjwd6i9

Anti-PAD Abs seen in 1/3 of pts at-risk for RA and 1/3 of pts w/ CSA. Implications? Possible predictive value of anti-PAD Abs in RA dse progression? @RheumNow #ACR20 abs0761 #ACRbest https://t.co/VpkjwU2YZm

Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug. #RheumTwitter #lupus Abs#0849 #ACR20 @RheumNow https://t.co/8a6OcZmOso

• Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrate…

The development of biologics started with diphtheria- history of Medicine! Look how far we have come now prescribing over 50 different types of biologics! @RheumNow #acr20 https://t.co/XbygK5g7ON

BKZ tx improved BASDAI total and single question scores related to fatigue and neck, back and hip pain in pts with PsA. #ABS0906 #ACR20 @RheumNow https://t.co/GzpJfkwvL5 https://t.co/KnJAqAKlqq

• Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue …